PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma - PubMed (original) (raw)
. 2008 Mar 15;111(6):3220-4.
doi: 10.1182/blood-2007-05-085159. Epub 2008 Jan 18.
Affiliations
- PMID: 18203952
- DOI: 10.1182/blood-2007-05-085159
Free article
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Ryo Yamamoto et al. Blood. 2008.
Free article
Abstract
Programmed death-1 (PD-1)-PD-1 ligand (PD-L) signaling system is involved in the functional impairment of T cells such as in chronic viral infection or tumor immune evasion. We examined PD-L expression in lymphoid cell lines and found that they were up-regulated on Hodgkin lymphoma (HL) and several T-cell lymphomas but not on B-cell lymphomas. PD-L expression was also demonstrated in primary Hodgkin/Reed-Sternberg (H/RS) cells. On the other hand, PD-1 was elevated markedly in tumor-infiltrating T cells of HL, and was high in the peripheral T cells of HL patients as well. Blockade of the PD-1 signaling pathway inhibited SHP-2 phosphorylation and restored the IFN-gamma-producing function of HL-infiltrating T cells. According to these results, deficient cellular immunity observed in HL patients can be explained by "T-cell exhaustion," which is led by the activation of PD-1-PD-L signaling pathway. Our finding provides a potentially effective immunologic strategy for the treatment of HL.
Similar articles
- Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L, Adam J, Gravelle P, Marty V, Danu A, Lazarovici J, Ribrag V, Bosq J, Camara-Clayette V, Laurent C, Ghez D. El Halabi L, et al. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):257-266.e3. doi: 10.1016/j.clml.2020.11.009. Epub 2020 Nov 12. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33277223 - Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S. Michot JM, et al. Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Eur J Cancer. 2017. PMID: 28892775 Review. - Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.
Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Dong H, Ansell SM. Jalali S, et al. Blood Cancer J. 2019 Feb 19;9(3):22. doi: 10.1038/s41408-019-0185-9. Blood Cancer J. 2019. PMID: 30783096 Free PMC article. - PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. Xie W, et al. Curr Hematol Malig Rep. 2020 Aug;15(4):372-381. doi: 10.1007/s11899-020-00589-y. Curr Hematol Malig Rep. 2020. PMID: 32394185 Review. - Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC, Ansell S. Villasboas JC, et al. Cancer J. 2016 Jan-Feb;22(1):17-22. doi: 10.1097/PPO.0000000000000164. Cancer J. 2016. PMID: 26841012 Review.
Cited by
- Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.
Lin CC, Curigliano G, Santoro A, Kim DW, Tai D, Hodi FS, Wilgenhof S, Doi T, Sabatos-Peyton C, Szpakowski S, Chitnis S, Xyrafas A, Gutzwiller S, Pastore A, Mach N. Lin CC, et al. BMJ Open. 2024 Aug 29;14(8):e079132. doi: 10.1136/bmjopen-2023-079132. BMJ Open. 2024. PMID: 39209782 Free PMC article. Clinical Trial. - Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1.
Ludwig SD, Meksiriporn B, Tan J, Kureshi R, Mishra A, Kaeo KJ, Zhu A, Stavrakis G, Lee SJ, Schodt DJ, Wester MJ, Kumar D, Lidke KA, Cox AL, Dooley HM, Nimmagadda S, Spangler JB. Ludwig SD, et al. Cell Chem Biol. 2024 May 16;31(5):904-919.e11. doi: 10.1016/j.chembiol.2024.02.014. Epub 2024 Mar 27. Cell Chem Biol. 2024. PMID: 38547863 - Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis.
Pan Y, Cengiz R, Kluiver J, Diepstra A, Van den Berg A. Pan Y, et al. Cancers (Basel). 2024 Mar 12;16(6):1126. doi: 10.3390/cancers16061126. Cancers (Basel). 2024. PMID: 38539461 Free PMC article. Review. - Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.
Shang J, Hu S, Wang X. Shang J, et al. Exp Hematol Oncol. 2024 Feb 23;13(1):21. doi: 10.1186/s40164-024-00481-y. Exp Hematol Oncol. 2024. PMID: 38396050 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials